Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2020 09:00 ET | Source: CereSpir Inc.

CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- CERESPIR INCORPORATED, a pharmaceutical company engaged in the discovery and development of disease modifying therapeutics for the treatment of...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

CERESPIR INCORPORATED und das NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE geben positive Daten bekannt, die eine vorteilhafte Wirkung des in der klinischen Erprobung befindlichen Wirkstoffs Itanapraced von CERESPIR in einem LRRK2-Modell der Parkinson-Krankheit zeigen

Itanapraced blockiert die LRRK2-Expression und die LRRK2-vermittelte NeurotoxizitätItanapraced kann nun in einer Phase-II-Studie an Patienten mit Parkinson-Krankheit mit und ohne genetische Mutation...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

CERESPIR INCORPORATED et le NATIONAL NEUROSCIENCE INSTITUTE – SINGAPOUR annoncent des données positives montrant les effets bénéfiques du composé Itanapraced de CERESPIR au stade clinique dans un modèle LRRK2 de la maladie de Parkinson

Itanapraced bloque l'expression de LRRK2 et la neurotoxicité à médiation par LRRK2Itanapraced est prêt à passer à la Phase 2 chez les patients atteints de la maladie de Parkinson avec ou sans mutation...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

セレスピールとシンガポール国立神経科学研究所が、パーキンソン病のLRRK2モデルにおけるセレスピールの臨床適用候補化合物イタナプラセド (Itanapraced) の有益効果を示す肯定的データを発表

イタナプラセドは、LRRK2発現およびLRRK2媒介性神経毒性を阻害するイタナプラセドは、パーキンソン病患者の遺伝的変異の有無にかかわらず、第2相臨床試験に進む準備が完了ニューヨークおよびシンガポール発, Dec. 11, 2018 (GLOBE NEWSWIRE) -- 神経変性疾患の治療のための疾患修飾治療の発見および開発に従事する製薬会社セレスピール (CERESPIR...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

CERESPIR INCORPORATED dan INSTITUT NEUROSAINS KEBANGSAAN SINGAPURA Mengumumkan Data Positif yang Menunjukkan Kesan Bermanfaat Sebatian Peringkat Klinikal Itanapraced CERESPIR dalam Model LRRK2 Penyakit Parkinson

Itanapraced menghalang pernyataan LRRK2 dan keneurotoksikan akibat LRRK2tanapraced sedia untuk dipertingkatkan ke Fasa 2 pada pesakit berpenyakit Parkinson dengan dan tanpa mutasi genetik NEW YORK...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

CERESPIR有限公司及新加坡國立神經科學研究院宣佈正面數據顯示，CERESPIR公司臨床階段化合物Itanapraced對帕金森病LRRK2模型帶來有益效果

Itanapraced 阻斷LRRK2的表達及 LRRK2介導的神經毒性Itanapraced 準備進入攜帶及非攜帶基因突變的帕金森病患者2期臨床試驗紐約和新加坡, Dec. 11, 2018 (GLOBE NEWSWIRE) --...
December 10, 2018 18:15 ET | Source: CereSpir Inc.

CERESPIR有限公司和新加坡国立神经科学研究院宣布阳性数据显示，CERESPIR公司临床阶段化合物Itanapraced对帕金森病LRRK2模型具有益效果

Itanapraced 阻断LRRK2的表达及 LRRK2介导的神经毒性Itanapraced 准备进入携带及非携带基因突变的帕金森病患者2期临床试验纽约和新加坡, Dec. 11, 2018 (GLOBE NEWSWIRE) --...
December 10, 2018 09:00 ET | Source: CereSpir Inc.

CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease

Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation NEW YORK and SINGAPORE,...
July 14, 2015 09:00 ET | Source: CereSpir Inc.

CereSpir Incorporated Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

NEW YORK, July 14, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced...
July 01, 2015 09:00 ET | Source: CereSpir Inc.

CereSpir Incorporated Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

NEW YORK, July 1, 2015 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company with a novel approach to treat neurodegenerative diseases by harnessing the innate immune system, today announced the...